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BSTRACT
 
Background
 
In patients with idiopathic deep
venous thrombosis, continuing anticoagulant therapy
beyond three months is associated with a reduced
incidence of recurrent thrombosis during the period
of therapy. Whether this benefit persists after antico-
agulant therapy is discontinued is controversial.
 
Methods
 
Patients with a first episode of idiopathic
proximal deep venous thrombosis who had completed
three months of oral anticoagulant therapy were ran-
domly assigned to the discontinuation of oral antico-
agulants or to their continuation for nine additional
months. The primary study outcome was recurrence
of symptomatic, objectively confirmed venous throm-
boembolism during at least two years of follow-up.
 
Results
 
The primary intention-to-treat analysis
showed that of 134 patients assigned to continued oral
anticoagulant therapy, 21 had a recurrence of venous
thromboembolism (15.7 percent; average follow-up,
37.8 months), as compared with 21 of 133 patients as-
signed to the discontinuation of oral anticoagulant
therapy (15.8 percent; average follow-up, 37.2 months),
resulting in a relative risk of 0.99 (95 percent confi-
dence interval, 0.57 to 1.73). During the initial nine
months after randomization (after all patients received
three months of therapy), 1 patient had a recurrence
while receiving oral anticoagulant therapy (0.7 per-
cent), as compared with 11 of the patients assigned to
the discontinuation of oral anticoagulant therapy (8.3
percent, P=0.003). The incidence of recurrence after
the discontinuation of treatment was 5.1 percent per
patient-year in patients in whom oral anticoagulant
therapy was discontinued after 3 months and 5.0
percent per patient-year in patients who received an
additional 9 months of oral anticoagulant therapy.
None of the recurrences were fatal. Four patients had
nonfatal major bleeding during the extended period of
anticoagulant therapy (3.0 percent).
 
Conclusions
 
In patients with idiopathic deep
venous thrombosis, the clinical benefit associated
with extending the duration of anticoagulant therapy
to one year is not maintained after the therapy is dis-
continued. (N Engl J Med 2001;345:165-9.)
 
Copyright © 2001 Massachusetts Medical Society.
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HE optimal duration of treatment with oral
anticoagulant agents after deep venous
thrombosis reflects a balance between the
risk of recurrence when treatment is discon-
tinued and the risk of bleeding resulting from con-
tinued anticoagulant therapy.
 
1-3
 
 The risk of recurrent
thromboembolism after the discontinuation of anti-
coagulant therapy is highly dependent on patient-spe-
cific risk factors.
 
4-7
 
 Patients who have thrombosis in
the absence of known risk factors (i.e., who have idio-
pathic venous thrombosis) or in association with per-
sistent risk factors (such as cancer and thrombophil-
ia) are at higher risk of recurrence than patients with
thrombosis associated with time-limited, reversible risk
factors.
 
4-7
 
 In this last group of patients, oral anticoag-
ulant therapy can be limited to three months after the
elimination of the risk factor. More prolonged courses
of anticoagulant therapy are recommended for patients
in whom thrombosis is associated with persistent risk
factors
 
2
 
; in addition, on the basis of the results of two
recent, adequately designed studies, longer therapy
should be considered for patients with idiopathic
thrombosis.
 
5,8
 
In the more recent of the two studies, Kearon et
al. randomly assigned patients with idiopathic venous
thromboembolism who had received three months of
oral anticoagulant therapy to the discontinuation of
anticoagulant therapy or its continuation for two ad-
ditional years.
 
8
 
 The study was terminated early be-
T
The New England Journal of Medicine 
Downloaded from nejm.org at OSPEDALE VARESE on February 29, 2012. For personal use only. No other uses without permission. 
 Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
 166
 
·
 
N Engl J Med, Vol. 345, No. 3
 
·
 
July 19, 2001
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
 
cause of the impressive reduction in the risk of recur-
rence of thromboembolic events during therapy in the
group of patients assigned to continued anticoagulant
therapy. Whether the advantage observed in patients
in whom therapy is continued for an extended period
is maintained after that therapy has been stopped re-
mains unclear.
We conducted a multicenter, randomized trial to
evaluate the long-term clinical benefit of extending to
one year the three-month course of oral anticoagulant
therapy after a first episode of idiopathic proximal deep
venous thrombosis. The primary outcome of the study
was the symptomatic, objectively confirmed recurrence
of venous thromboembolism during at least two years
of follow-up.
 
METHODS
 
Patients
 
Consecutive patients ranging from 15 to 85 years old with a first
episode of symptomatic idiopathic proximal deep venous thrombo-
sis, as demonstrated on compression ultrasonography or venogra-
phy, were eligible for the study, provided that they had completed
three uninterrupted months of oral anticoagulant therapy without
having a recurrence of thromboembolism or bleeding. Idiopathic
deep venous thrombosis was defined as thrombosis occurring in the
absence of known cancer, known thrombophilia, prolonged immo-
bilization (i.e., lasting more than seven days) from any cause, recent
trauma or surgery (i.e., within the previous three months), preg-
nancy, recent childbirth, or the use of oral contraceptives. Systematic
screening for occult cancer or thrombophilia was not performed
before patients were enrolled in the study. Patients who required
prolonged anticoagulant therapy for reasons other than venous
thromboembolism were excluded from the study, as were patients
with major psychiatric disorders, patients with a life expectancy
shorter than two years, those who could not return for the follow-
up visits, and those who declined to participate. The study protocol
was approved by the institutional review boards of the participating
hospitals; all patients gave written informed consent.
 
Study Design and Interventions
 
The Warfarin Optimal Duration Italian Trial was a randomized,
multicenter, open trial with independent, blinded assessment of the
outcome events. The study was designed to evaluate the clinical ben-
efit of extending to one year the three-month course of oral anti-
coagulant therapy after a first episode of idiopathic proximal deep
venous thrombosis. After three months of therapy with warfarin (in
97 percent of the cases) or acenocoumarol, patients were randomly
assigned to discontinue oral anticoagulant therapy or to continue it
for nine additional months.
The dose of warfarin or other oral anticoagulant was adjusted
to achieve a target international normalized ratio (INR) between
2.0 and 3.0. The therapy was monitored in anticoagulant clinics
associated with the 10 study centers, all in Italy.
 
Outcome Measures
 
The primary outcome of the study was the recurrence of symp-
tomatic, objectively confirmed deep venous thromboembolism dur-
ing a follow-up period of at least two years. The criteria for the di-
agnosis of recurrent deep venous thrombosis were positive results
on compression ultrasonography or venography in the contralateral
leg; an intraluminal filling defect in the ipsilateral leg that was visible
on a venogram; or the finding on ultrasonography of a newly non-
compressible venous segment in the ipsilateral leg. The criteria for
the diagnosis of pulmonary embolism were a diagnostic pulmonary
angiogram, a ventilation–perfusion lung scan indicating a high
probability of pulmonary embolism, or an indeterminate lung scan
with a high degree of clinical suspicion of pulmonary embolism in
a patient with an objectively diagnosed asymptomatic recurrence of
deep venous thrombosis.
Bleeding was defined as major if it was clinically overt and asso-
ciated with either a decrease in the hemoglobin level of at least 2 g
per deciliter or the need for the transfusion of 2 or more units of red
cells; if it was retroperitoneal or intracranial; or if it warranted the
permanent discontinuation of the study drug. Deaths were classified
as the result of pulmonary embolism, bleeding, or another identi-
fiable cause or as unexplained.
All suspected outcome events (recurrent thromboembolism and
bleeding episodes) and all deaths were reviewed centrally, for both
the interim and final analyses, by an independent, external adjudi-
cation committee whose members were unaware of the treatment-
group assignments.
 
Follow-up
 
Patients were instructed to return for follow-up visits at 3, 6, and
12 months after randomization and every 6 months thereafter until
the completion of the study. Patients were asked to return to the
study center immediately if symptoms developed that were sugges-
tive of recurrent venous thromboembolism or bleeding. For all pa-
tients who died during the follow-up period, the date and cause of
death were documented. We attempted to gain permission for au-
topsies of all patients in whom a pulmonary embolism could not be
excluded as the cause of death.
 
Statistical Analysis
 
The primary analysis of efficacy was a comparison of the rates of
symptomatic, objectively confirmed recurrence of venous thrombo-
embolism in the two treatment groups during a follow-up period of
at least two years after randomization. The primary analysis was per-
formed on an intention-to-treat basis. However, since some patients
discontinued oral anticoagulant therapy before its scheduled com-
pletion, continued to use the anticoagulant after its scheduled com-
pletion, or resumed its use after the scheduled interruption, a per-
protocol analysis including only the patients who completed
treatment according to the study protocol was also performed.
On the basis of the results of previous studies, it was assumed
that the rate of recurrence of venous thromboembolism would be
15 percent over two years of postrandomization follow-up in pa-
tients assigned to the discontinuation of oral anticoagulant thera-
py.
 
5,6
 
 We also assumed that the prolongation of oral anticoagulant
therapy by nine months would produce a 50 percent reduction in
the risk of recurrence. Given these assumptions, we needed 246 pa-
tients in each group to detect a difference of this magnitude between
groups with a power of 80 percent and a type I error rate of 5 per-
cent. In order to avoid the exposure of the study patients to an in-
effective or dangerous therapeutic regimen, one prespecified interim
analysis of efficacy and safety was planned after the randomization
of the first 246 patients. The following criteria for stopping the
trial were defined a priori: an overall rate of recurrence of thrombo-
embolic events lower than 7.5 percent; an unequivocal reduction in
the rate of recurrent venous thromboembolism in the patients as-
signed to continued therapy (P<0.001 by a one-sided test); a risk
of recurrence in the continued-therapy group that was less than 25
percent lower than that in the group assigned to discontinue ther-
apy, in the presence of the expected rate of events (15±2.5 percent)
in the latter group; or a rate of major bleeding higher than 5 percent
in the continued-therapy group.
The cumulative hazard of recurrent venous thromboembolism
was calculated according to the Kaplan–Meier life-table method.
 
9
 
Rates of recurrence in the two groups were compared with the use
of the log-rank test.
 
10
 
RESULTS
 
Patients
 
The recruitment of patients began in January 1995
and was stopped in June 1998 after the inclusion of
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267 patients, when the results of the interim analysis
were available and showed a difference of less than 25
percent in the risk of recurrence. At that time, throm-
boembolic events had recurred in 16 of the 123 pa-
tients assigned to the discontinuation of oral antico-
agulant therapy (13.0 percent) and in 15 of the 123
patients assigned to the continuation of oral antico-
agulant therapy (12.2 percent), corresponding to a dif-
ference in risk of 6.2 percent. Follow-up was contin-
ued until the last enrolled patient completed two years
of follow-up.
At the time of randomization, 290 consecutive pa-
tients met the criteria for inclusion, among whom 23
also met one of the criteria for exclusion. The reasons
for the exclusion of patients were contraindications to
long-term anticoagulant therapy (in eight patients),
other indications for long-term anticoagulant therapy
(in six patients), declining to give consent (in six pa-
tients), and inability to return for follow-up visits (in
three patients). Therefore, 267 patients were enrolled
in the study, 133 in the group assigned to discontinue
oral anticoagulant therapy and 134 in the group as-
signed to continue therapy.
The base-line characteristics of the patients in the
two treatment groups were similar. The average age
was 67.7±7.3 years among the patients assigned to
discontinue therapy and 66.8±6.7 years among those
assigned to continue therapy; men accounted for 61.2
percent of the patients assigned to discontinue therapy
and 54.5 percent of those assigned to continue ther-
apy. Approximately 20 percent of patients in both
groups received low-molecular-weight heparin as an
initial treatment; the remaining patients received intra-
venous unfractionated heparin. Four patients declined
to continue oral anticoagulant therapy after random-
ization. Oral anticoagulant therapy was prematurely
and permanently discontinued in nine patients as-
signed to the continuation of therapy. Oral antico-
agulant therapy was prolonged beyond its scheduled
cessation in two patients assigned to discontinue ther-
apy and was resumed after the scheduled cessation in
five patients assigned to discontinue therapy. On the
basis of the linear interpolation of INR results between
tests, we estimate that the INR was between 2.0 and
3.0 for an average of 81 percent of the time during
the nine months of extended anticoagulant therapy.
During the follow-up period, cancer was newly diag-
nosed in five patients — three assigned to continue
therapy and two to discontinue therapy (1.9 percent
of the total cohort; lung cancer in two patients and
bladder cancer, breast cancer, and prostate cancer in
one patient each).
 
Recurrent Venous Thromboembolism
 
The primary intention-to-treat analysis showed that
of the 134 patients assigned to continue therapy, 21
had recurrent venous thromboembolism (15.7 per-
cent; average follow-up, 37.8 months), as did 21 of the
133 patients assigned to discontinue therapy (15.8
percent; average follow-up, 37.2 months), resulting in
a relative risk of 0.99 (95 percent confidence interval,
0.57 to 1.73). The features of the recurrences are
shown in Table 1. All episodes of recurrent venous
thromboembolism were idiopathic, and none were fa-
tal. The average time to recurrence was 11.2 months
from randomization in the patients assigned to dis-
continue therapy and 16.0 months from randomiza-
tion in those assigned to continue therapy. The cumu-
lative hazard of recurrent venous thromboembolism
in the two groups according to the intention-to-treat
analysis is shown in Figure 1 (log-rank statistic=0.02,
P=0.88). Of the 115 patients assigned to continue
therapy who were included in the per-protocol analy-
sis, 18 had a recurrence of venous thromboembolism
(15.7 percent), as compared with 21 of the 126 pa-
tients assigned to discontinue therapy who were in-
cluded in this analysis (16.7 percent), resulting in a
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Figure 1.
 
 Cumulative Hazard of Recurrent Venous Thromboem-
bolism in Patients Assigned to Discontinue Oral Anticoagulant
Therapy and Those Assigned to Continue Oral Anticoagulant
Therapy (Intention-to-Treat Population).
0.00
0.30
0 36
0.05
0.10
0.15
0.20
0.25
3 6 9 12 15 18 21 24 27 30 33
Months
Assigned to discontinueE
therapy
Assigned to continueE
therapy
C
u
m
u
la
ti
ve
 H
az
ar
d
 o
f 
R
ec
u
rr
en
ce
The New England Journal of Medicine 
Downloaded from nejm.org at OSPEDALE VARESE on February 29, 2012. For personal use only. No other uses without permission. 
 Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
 168
 
·
 
N Engl J Med, Vol. 345, No. 3
 
·
 
July 19, 2001
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
 
relative risk of 0.94 (95 percent confidence interval,
0.54 to 1.67).
An intention-to-treat analysis showed that the risk
of recurrence during the first nine months of follow-
up was lower among the patients assigned to continue
therapy (4 patients; 3.0 percent; 4.6 percent per pa-
tient-year) than in those assigned to discontinue ther-
apy (11 patients; 8.3 percent; 12.3 percent per patient-
year; relative risk, as compared with patients assigned
to discontinue therapy, 0.36; 95 percent confidence
interval, 0.12 to 1.11). Three patients assigned to con-
tinue therapy who had recurrent thromboembolism
during the initial nine-month study period had pre-
maturely interrupted oral anticoagulant therapy (two
voluntarily and one because of major bleeding). Thus,
only one patient had a recurrence while receiving ac-
tive oral anticoagulant therapy (0.7 percent; 1.2 per-
cent per patient-year; relative risk as compared with
patients assigned to discontinue therapy, 0.09; 95 per-
cent confidence interval, 0.02 to 0.69; P=0.003).
The incidence of recurrence after the discontinua-
tion of therapy was 5.1 percent per patient-year among
the patients assigned to discontinue therapy (95 per-
cent confidence interval, 3.2 to 7.5 percent; 21 events;
average interval since discontinuation, 37.2 months)
and 5.0 percent per patient-year in those assigned to
continue therapy (95 percent confidence interval, 3.1
to 7.8 percent; 17 events; average interval since dis-
continuation, 29.4 months).
 
Bleeding Complications
 
Four patients (3.0 percent) assigned to continue
therapy had nonfatal episodes of major bleeding while
receiving oral anticoagulant therapy (melena in three
patients and menorrhagia in one patient). None of
these patients had an INR above the therapeutic range
at the time of the episode. Two fatal episodes of bleed-
ing occurred in patients assigned to discontinue ther-
apy (1.5 percent) — one intracranial, 1 month after
the discontinuation of oral anticoagulant therapy, and
the other gastrointestinal, 12 months after discontin-
uation.
 
Deaths
 
Fourteen patients (5.2 percent) died during the
study period. Seven patients assigned to discontinue
therapy died — three from myocardial infarction, two
from heart failure, one from intracranial bleeding, and
one from gastrointestinal bleeding. Seven patients as-
signed to continue therapy died — three from myo-
cardial infarction, three from cancer, and one from res-
piratory failure.
 
Cumulative Adverse Outcomes
 
A total of 28 patients assigned to discontinue ther-
apy (21.1 percent) had at least one adverse outcome
(a symptomatic, objectively confirmed recurrence of
venous thromboembolism, major bleeding, or death),
as compared with 31 patients assigned to continue
therapy (23.1 percent) (Table 2). No adverse events
occurred in patients in whom therapy was extended
or resumed after its scheduled interruption or in any
of the four patients who declined to continue therapy
after randomization.
 
DISCUSSION
 
Kearon et al.
 
8
 
 showed that the rate of recurrence of
venous thromboembolism in patients with idiopathic
deep venous thrombosis who were assigned to receive
extended anticoagulant therapy was lower while they
were receiving that therapy than the rate of recurrence
in patients assigned to discontinue anticoagulant ther-
apy. The results of our study show that the clinical ben-
efit achieved during therapy when the three-month
course of oral anticoagulant therapy is extended to one
year is not maintained after the discontinuation of
therapy. Approximately two thirds of the recurrences
of thromboembolic events in both treatment groups
occurred during the first year after the discontinuation
of oral anticoagulant therapy. These findings suggest
that prolonging anticoagulant therapy beyond three
months in patients with idiopathic deep venous throm-
bosis simply delays recurrence until anticoagulant ther-
apy is stopped, rather than reducing the risk of recur-
rence.
Despite the fact that patients with a high risk of
bleeding were excluded from this study and that oral
anticoagulant therapy was monitored closely, 3 percent
of patients had major bleeding during the nine months
of extended oral anticoagulant therapy, a percentage
consistent with the rate of bleeding events in previ-
ous studies.
 
5,8
 
The results of this study apply only to patients with
idiopathic deep venous thrombosis as defined by the
study protocol. Patients with known permanent or
temporary risk factors were excluded from this study,
but systematic screening for thrombophilia and cancer
was not performed. Our findings are likely to apply
to the large majority of patients with a first episode of
apparently spontaneous deep venous thrombosis, since
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Major bleeding 2 (1.5) 4 (3.0)
Death 7 (5.3) 7 (5.2)
At least one adverse event 28 (21.1) 31 (23.1)
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they are currently not systematically screened for oc-
cult cancer and thrombophilia. Differences in the def-
inition of idiopathic venous thromboembolism and
in the duration of anticoagulant therapy could help
explain the differences between the outcome in our
study and those in other studies.
 
5,8
 
As in some previous studies, all recurrent thrombo-
embolic events were idiopathic,
 
8
 
 and more than half
involved the initially unaffected leg.
 
11
 
 The idiopathic
nature of the recurrences suggests that these events
could be prevented by continuous anticoagulant ther-
apy, but not by intermittent prophylaxis limited to the
times when temporary risk factors for deep venous
thrombosis are present. The recurrences in the con-
tralateral leg suggest that a persistent underlying hy-
percoagulable state, rather than residual anatomical
changes, accounts for the high risk of recurrence in
patients with idiopathic venous thrombosis who have
stopped oral anticoagulant therapy.
 
12
 
Our study was not a double-blind trial. However,
its findings are likely to be valid, since a number of
measures were taken to avoid bias. These were the en-
rollment of consecutive patients, central randomiza-
tion, follow-up of all patients who underwent random-
ization, the central adjudication of all outcome events
by a committee unaware of the treatment assignments,
the assessment of recurrences of venous thromboem-
bolism and bleeding events on the basis of predeter-
mined objective criteria, and the inclusion in the study
analysis of all patients randomly assigned to treatment
groups.
With respect to the primary a priori hypothesis,
this study shows that 15 percent of patients with pre-
sumed idiopathic proximal deep venous thrombosis
will probably have a recurrence in the first two to three
years after the discontinuation of anticoagulant ther-
apy. We confirmed that during extended oral antico-
agulant therapy, the rate of recurrence is negligible in
patients who actually continue therapy. The adminis-
tration of oral anticoagulants indefinitely could extend
the initial benefit, but such therapy carries the risk of
bleeding and is inconvenient. Anticoagulant therapy of
indefinite duration could be made safer by reducing
the doses of oral anticoagulants after an initial period
of treatment with the full dose. The development of
oral antithrombotic agents that have an improved safe-
ty profile and do not require laboratory monitoring
could certainly pave the way toward extending therapy
indefinitely. Patients with presumed idiopathic deep
venous thrombosis could be further categorized in
order to identify those at high risk for recurrence after
the discontinuation of anticoagulant therapy.
Studies assessing both the strategy of extending low-
dose anticoagulant therapy indefinitely and that of im-
proving risk stratification among patients with idio-
pathic venous thromboembolism have recently begun
or been planned. The results of these studies will prob-
ably define the optimal long-term treatment for pa-
tients with idiopathic deep venous thrombosis.
 
Presented in part at the 20th Congress of the International Society of
Thrombosis and Haemostasis, Washington, D.C., August 20, 1999.
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